Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults
Blood · 2022
DOI: 10.1182/blood.2022017118 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Blood, 2022. Verfasst von Paul Harker-Murray und 18 weiteren Autor:innen. Beteiligte Einrichtung: Children's Wisconsin, Milwaukee, WI. Hauptthemen laut MEDLINE: Hodgkin Disease, Immunoconjugates. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Children, adolescents, and young adults (CAYA) with relapsed/refractory classical Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous hematopoietic cell transplantation (auto-HCT) have poor survival outcomes. CheckMate 744, a phase 2 study for CAYA (aged 5-30 years) with relapsed/refractory cHL, evaluated a risk-stratified, response-adapted approach with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response. Risk stratification was primarily based on time to relapse, prior treatment, and presence of B symptoms. We present the primary analysis of the standard-risk cohort. Data from the low-risk cohort are reported separately. Patients received 4 induction cycles with nivolumab plus BV; those without CMR (Deauville score >3, Lugano 2014) received BV plus bendamustine intensification. Patients with CMR after induction or intensification proceeded to consolidation (high-dose chemotherapy/auto-HCT per protocol). Primary endpoint was CMR any time before consolidation. Forty-four patients were treated. Median age was 16 years. At a minimum follow-up of 15.6 months, 43 patients received 4 induction cycles (1 discontinued); 11 of whom received intensification, 32 proceeded to consolidation. CMR rate was 59% after induction with nivolumab plus BV, and 94% any time before consolidation (nivolumab plus BV ± BV plus bendamustine). One-year PFS rate was 91%. During induction, 18% of patients experienced grade 3/4 treatment-related adverse events. This risk-stratified, response-adapted salvage strategy had high CMR rates with limited toxicities in CAYA with relapsed/refractory cHL. Most patients did not require additional chemotherapy (bendamustine intensification). Additional follow-up is needed to confirm durability of disease control. ClinicalTrials.gov: NCT02927769.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Children's Wisconsin, Milwaukee, WI.
- University Hospital Justus Liebig University, Giessen, and Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle, Germany.
- Hôpital Robert-Debré Assistance Publique - Hôpitaux de Paris, Paris, France.
- Adolescent and Young Adult Oncology and Pediatric Radiotherapy Unit, Centro di Riferimento Oncologico Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.
- Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France.
- Johns Hopkins Hospital, Baltimore, MD.
ORCID-Profile: Christine Mauz-Körholz, Maurizio Mascarin, Auke Beishuizen, Kasey J Leger, Loredana Amoroso, Bradford S Hoppe
Zitieren
APA
Harker-Murray, P., Mauz-Körholz, C., Leblanc, T., Mascarin, M., Michel, G., Cooper, S., Beishuizen, A., Leger, K. J., Amoroso, L., Buffardi, S., Rigaud, C., Hoppe, B. S., Lisano, J., Francis, S., Sacchi, M., Cole, P. D., Drachtman, R. A., Kelly, K. M., & Daw, S. (2022). Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults. Blood. https://doi.org/10.1182/blood.2022017118
Vancouver
Harker-Murray P, Mauz-Körholz C, Leblanc T, Mascarin M, Michel G, Cooper S, et al. Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults. Blood. 2022. doi:10.1182/blood.2022017118
BibTeX
@article{HarkerMurray2022,
author = {Harker-Murray, Paul and Mauz-Körholz, Christine and Leblanc, Thierry and Mascarin, Maurizio and Michel, Gérard and Cooper, Stacy and Beishuizen, Auke and Leger, Kasey J and Amoroso, Loredana and Buffardi, Salvatore and Rigaud, Charlotte and Hoppe, Bradford S and Lisano, Julie and Francis, Stephen and Sacchi, Mariana and Cole, Peter D and Drachtman, Richard A and Kelly, Kara M and Daw, Stephen},
title = {Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults},
journal = {Blood},
year = {2022},
doi = {10.1182/blood.2022017118}
}
EUVIMED